Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Fiche publication
Date publication
janvier 2011
Journal
Clinics and research in hepatology and gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Samalin E, Afchain P, Thézenas S, Abbas F, Romano O, Guimbaud R, Bécouarn Y, Desseigne F, Edeline J, Mitry E, Bouché O, Adenis A, Aparicio T, Dorval E, Kramar A, Ychou M
Lien Pubmed
Résumé
The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status. We evaluated the efficacy of FOLFIRI regimen in a large retrospective series of MGA pts.
Mots clés
Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, administration & dosage, Antineoplastic Agents, Phytogenic, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Camptothecin, administration & dosage, Esophageal Neoplasms, drug therapy, Esophagogastric Junction, Female, Fluorouracil, administration & dosage, Humans, Male, Middle Aged, Retrospective Studies, Stomach Neoplasms, drug therapy
Référence
Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):48-54